Page 62 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences Youth brain health check and dysregulation

6 Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Purba Medinipur, West
Bengal, India
7 Division of Personalized Recovery Science, Transplicegen Therapeutics, Llc., Austin, Tx., United of States
8 Department of Psychiatry, University of Vermont, Burlington, Vermont, United States of America
9 Department of Psychiatry, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
10 Division of Personalized Medicine, Ketamine Clinic of South Florida, Pompano Beach, Florida, United States of America
11 Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
12 Department of Family Medicine, Jefferson Health Northeast, Philadelphia, Pennsylvania, United States of America
13 Department of Psychology and Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on
Addictions, University of Buffalo, Buffalo, New York, United States of America
14 Cambridge Health Alliance, Harvard Medical School, Cambridge, Massachusetts, United States of America
15 Department of Anatomy, Howard University School of Medicine, Washington, D.C., United States of America
16 Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, United States of America
17 Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania,
United States of America
18 Department of Human Development, California State University at Long Beach, Long Beach, California, United States of America
19 Awareness Integration Institute, San Clemente, California, United States of America
20 Department of Health Science, California State University at Long Beach, Long Beach, California, United States of America
21 Department of Psychiatry, University California, UC Riverside School of Medicine, Riverside, California, United States of America
22 Future Biologics, Lawrenceville, Georgia, United States of America
23 Division of Pediatric Neurology, University of Missouri Health Care-Columbia, Columbia, Missouri, United States of America
24 Department of Psychiatry, Mt. Sinai School of Medicine, New York City, New York, United States of America

1. Introduction It is well established that dopamine resistance in
individuals with food and drug addiction is caused by
The purpose of the brain health check (BHC) is to integrate dysfunctional genetic neurotransmitter polymorphisms,
objective assessments across cognition, neurological such as the A1 allele of the DRD2 gene, and epigenetic
imaging, psychiatry, and genomics to identify youths who insults. A burgeoning line of evidence shows that a natural,
are at risk for juvenile mental health problems, criminal non-addictive, and safe putative D2 agonist may aid in the
activities, addiction, and other behaviors associated with treatment of and recovery from these RDS behaviors in
reward deficiency syndrome (RDS). Identifying vulnerable patients addicted to substances. The impact of the patented
youths through these assessments can provide insights into KB220 nutrigenomic technology, known as “Synaptamine
proper interventions, such as genome-matched amino acid Complex,” acts as an activator of the mesolimbic system,
therapies that can treat reward/dopamine dysregulation as observed through quantitative electroencephalography
and prevent the inheritance of epigenetic insults associated (qEEG) imaging. A published pilot study demonstrated
with addiction to future generations. Amidst the increasing that the intravenous administration of KB220 was
drug abuse crisis in the United States (US) and the potential observed to normalize the aberrant electrophysiological
for long-term enormous societal costs, a brain research parameters of the reward circuitry site. The study also
1
consortium developed this approach. The group is comprised revealed that the qEEG graphs of an alcoholic and a heroin
experienced teachers, educators, drug abuse counselors, abuser with existing abnormalities (widespread theta and
psychiatrists, clinicians, scientists, neuroscientists, geneticists, alpha activity, respectively) during protracted abstinence
and addiction medicine physicians, who encourage the were significantly normalized after the administration of a
adoption of the standardized BHC in K1–K12 education. In single intravenous dose of KB220® Synaptamine Complex
addition, they endorse basic and clinical scientific research Formulation. Both patients were genotyped for several
1
into brain health prophylaxis for developing brains. neurotransmitter reward genes to determine if they carried
2. Understanding reward dysregulation any putative dopaminergic risk alleles that may predispose
and potential therapeutic approaches them to alcohol or heroin dependence, respectively. The
genes examined included the dopamine transporter
As defined in the Sage Encyclopedia of Psychiatric (DAT1, locus symbol SLC6A3), dopamine D4 receptor
Disorders (2017), there is emerging evidence of an over- exon 3 VNTR (DRD4), DRD2 TaqIA (rs1800497), COMT
representation of the antecedent to RDS, encompassing val158 met SNP (rs4680), monoamine oxidase A upstream
both substance- and non-substance-related addictive VNTR (MAOA-uVNTR), and serotonin transporter-linked
behaviors, within the general US population. polymorphic region (5HTTLPR, locus symbol SLC6A4). It

Volume 7 Issue 2 (2024) 2 doi: 10.36922/itps.1472